Humana Inc.
NYSE:HUMMedical - Healthcare Plans
+$0.70 today
- Market cap
- $46.32B
- Beta
- 0.77
- P/E (TTM)
- 38.6
- EPS (TTM)
- $9.39
- Dividend yield
- 0.98%
Volume 4.06M
Average 1.72M
HUM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Humana Inc.NYSE: HUM
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 28.7% from a year ago
Cash & equivalents stood at $6.94B at the end of Q3 FY2026, up 28.7% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at -6.0% a year.
Context
- Cash & equivalents amounted to 12.1% of total assets at the end of Q3 FY2026, up 1.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +28.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 4.2B USD
- Year-over-year change
- +89.1%
- 4-year CAGR
- +5.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.2B | +89.1% |
| FY2024 | 2024-12-31 | 2.22B | -52.7% |
| FY2023 | 2023-12-31 | 4.69B | -7.3% |
| FY2022 | 2022-12-31 | 5.06B | +49.1% |
| FY2021 | 2021-12-31 | 3.39B | — |
Cash & Equivalents vs competitors
How HUM compares with its peers on the latest reported figures
- HUM's Sep 2026 cash & equivalents of $6.94B is the 5th highest of the 9 companies compared; the peer median is $8.27B.
- Its year-over-year change of +28.7% is the 4th highest of 9, against a peer median of +12.4%.
- Cash & equivalents amounts to 12.1% of total assets for HUM, versus a peer median of 18.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $25.85B | -5.0% | +1.4% | 8.3% | |
| Jun 2026 | $24.15B | +66.4% | +14.0% | 29.1% | |
| Jun 2026 | $11.33B | -3.9% | -13.0% | 4.5% | |
| Sep 2026 | $10.35B | +18.8% | +8.7% | 8.1% | |
| Sep 2026 | $6.94B | +28.7% | -6.0% | 12.1% | |
| Sep 2026 | $6.19B | +2.7% | +9.0% | 3.9% | |
| Sep 2026 | $4.48B | +6.1% | +2.0% | 28.6% | |
| Jun 2026 | $4.08B | +56.8% | +21.2% | 36.3% | |
| Mar 2026 | $1.41B | +216.3% | +12.2% | 111.9% | |
| Peer median (excluding HUM) | $8.27B | +12.4% | +8.9% | 18.4% | |
Competitors are the stored peer set for HUM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.39B | 5.06B | 4.69B | 2.22B | 4.2B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.81B | 1.67B | 2.04B | 2.7B | 3.27B |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 5.21B | 6.74B | 6.73B | 4.93B | 7.47B |
| Property, Plant & Equipment (Net) | 3.75B | 3.74B | 3.54B | 2.98B | 2.72B |
| Goodwill | 11.09B | 9.14B | 9.55B | 9.63B | 9.69B |
| Intangible Assets | 2.64B | 1.77B | 1.69B | 1.44B | 1.13B |
| Long-term Investments | 14.11B | 15.01B | 17.75B | 19.33B | 16.83B |
| Tax Assets | 578M | 851M | 48M | 260M | 84M |
| Other Non-current Assets | 7.37B | 6.49B | 7.58B | 7.74B | 10.83B |
| Total Non-current Assets | 39.54B | 36.99B | 40.16B | 41.39B | 41.28B |
| Total Assets | 44.75B | 43.73B | 46.89B | 46.31B | 48.75B |
| Account Payables | 8.1B | 9.08B | 10.07B | 10.27B | 9.81B |
| Short-term Debt | 2.14B | 2.26B | 1.61B | 724M | 150M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 254M | 286M | 266M | 260M | 356M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 10.49B | 11.63B | 11.95B | 11.26B | 10.31B |
| Long-term Debt | 10.54B | 9.03B | 10.21B | 11.14B | 12.37B |
| Deferred Tax Liabilities | 1.28B | 878M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.79B | 6.36B | 7.97B | 7.07B | 7.91B |
| Total Non-current Liabilities | 18.15B | 16.72B | 18.63B | 18.61B | 20.7B |
| Total Liabilities | 28.65B | 28.36B | 30.57B | 29.87B | 31.01B |
| Common Stock | 33M | 33M | 33M | 33M | 33M |
| Retained Earnings | 23.09B | 25.49B | 27.54B | 28.32B | 29.08B |
| Accumulated OCI | 42M | (1.3B) | (999M) | (1.07B) | (633M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 23M | 59M | 56M | 70M | 80M |
| Total Equity | 16.1B | 15.37B | 16.32B | 16.45B | 17.74B |
| Total Debt | 13.23B | 11.75B | 12.27B | 12.26B | 12.94B |
| Net Debt | 9.83B | 6.69B | 7.58B | 10.04B | 8.74B |
Humana Inc.
NYSE:HUM
Intrinsic Alpha fair value
Locked
Current Price
$385.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.